{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:23:07Z","timestamp":1785835387632,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.mcna.2013.10.011","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T15:49:38Z","timestamp":1385048978000},"page":"17","source":"Crossref","is-referenced-by-count":15,"title":["REMOVED: An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C"],"prefix":"10.1016","volume":"98","author":[{"given":"Jawad A.","family":"Ilyas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2013.10.011_bib1","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/hep.1840360705","article-title":"The burden of hepatitis C in the United States","volume":"36","author":"Kim","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2013.10.011_bib2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2013.10.011_bib3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2013.10.011_bib4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2013.10.011_bib5","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2013.10.011_bib6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2004.02.007","article-title":"Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3","volume":"40","author":"Zeuzem","year":"2004","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.mcna.2013.10.011_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0065-3527(04)63002-8","article-title":"Novel insights into hepatitis C virus replication and persistence","volume":"63","author":"Bartenschlager","year":"2004","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.mcna.2013.10.011_bib8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature02099","article-title":"An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus","volume":"426","author":"Lamarre","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.mcna.2013.10.011_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2036.2010.04317.x","article-title":"Review article: specifically targeted anti-viral therapy for hepatitis C\u2013a new era in therapy","volume":"32","author":"Lange","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mcna.2013.10.011_bib10","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2013.10.011_bib11","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2013.10.011_bib12","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2013.10.011_bib13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2010.10.046","article-title":"Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C","volume":"140","author":"Marcellin","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mcna.2013.10.011_bib14","first-page":"427A","article-title":"Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment naive patients: final results of phase 3 ADVANCE study","volume":"52","author":"Jacobson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2013.10.011_bib15","first-page":"LB-2","article-title":"Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment naive genotype 1 HCV patients who achieved an extended viral response: final results of phase 3 ILLUMINATE study","volume":"52","author":"Sherman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2013.10.011_bib16","unstructured":"Vertex\u2019s and Tibotec [press release]; Cambridge (MA): Vertex Pharmaceuticals; September 7, 2010."},{"key":"10.1016\/j.mcna.2013.10.011_bib17","first-page":"436A","article-title":"Long term follow up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study","volume":"52","author":"Zeuzem","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2013.10.011_bib18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2013.10.011_bib19","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir with peginterferon\/ribavirin for untreated chronic hepatitis C","volume":"364","author":"Poordad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2013.10.011_bib20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for treatment-resistant chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2013.10.011_bib21","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1016\/S0168-8278(11)60483-2","article-title":"Four-week therapy with peginterferon alfa-2b\/ribavirin effectively predicts sustained virologic response in treatment-naive and treatment-experienced patients with HCV-1 treated with boceprevir plus peginterferon alfa-2b\/ribavirin","volume":"54","author":"Vierling","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.mcna.2013.10.011_bib22","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/S0168-8278(11)60486-8","article-title":"Predictors of sustained virologic response among treatment-experienced patients with hepatitis C virus genotype 1 when re-treated with boceprevir plus peginterferon alfa-2b\/ribavirin","volume":"54","author":"Zeuzem","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.mcna.2013.10.011_bib23","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mcna.2013.10.011_bib24","doi-asserted-by":"crossref","first-page":"36784","DOI":"10.1074\/jbc.M506462200","article-title":"In\u00a0vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061","volume":"280","author":"Lin","year":"2005","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.mcna.2013.10.011_bib25","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/AAC.48.12.4784-4792.2004","article-title":"Combination of a hepatitis C virus NS3-NS4A protease inhibitor and \u03b1 interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells","volume":"48","author":"Lin","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mcna.2013.10.011_bib26","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1128\/AAC.50.5.1813-1822.2006","article-title":"VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells","volume":"50","author":"Lin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mcna.2013.10.011_bib27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.21781","article-title":"Telaprevir and pegylated interferon-\u03b1-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients","volume":"46","author":"Kieffer","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2013.10.011_bib28","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1128\/AAC.01598-08","article-title":"GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796","volume":"53","author":"McCown","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mcna.2013.10.011_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2005.12.003","article-title":"Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034","volume":"70","author":"Tong","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1016\/j.mcna.2013.10.011_bib30","doi-asserted-by":"crossref","first-page":"S470","DOI":"10.1016\/S0168-8278(10)61207-X","article-title":"Long term outcomes following combination treatment with boceprevir plus pegintron\/ribavirin (P\/R) in patients with chronic hepatitis C genotype 1 (CHC-G1)","volume":"52","author":"Vierling","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"20","key":"10.1016\/j.mcna.2013.10.011_bib31","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.mcna.2013.10.011_bib32","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2013.10.011_bib33","first-page":"614","article-title":"Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections","volume":"8","author":"Beaulieu","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.mcna.2013.10.011_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.22357","article-title":"R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin","volume":"48","author":"Pockros","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2013.10.011_bib35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jac\/dkp388","article-title":"Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)","volume":"65","author":"Kieffer","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.mcna.2013.10.011_bib36","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1128\/AAC.01599-08","article-title":"Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"53","author":"Shi","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.mcna.2013.10.011_bib37","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00307-11","article-title":"Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase","volume":"55","author":"Shih","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mcna.2013.10.011_bib38","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1016\/S0168-8278(10)61190-7","article-title":"Once daily NS5A Inhibitor(BMS-790052) plus peginterferon-\u03b1 2a and ribavirin produces high rates of extended rapid virologic response in treatment naive HCV genotype 1 subjects: phase 2a trial","volume":"52","author":"Pol","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2013.10.011_bib39","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2013.10.011_bib40","unstructured":"A study on the combination of RO5024048 and ritonavir-boosted danoprevir with and without Copegus (Ribavirin) in interferon-na\u00efve patients with chronic hepatitis C genotype 1 (INFORM-SVR). 2011. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01278134. Accessed February 25, 2011."},{"key":"10.1016\/j.mcna.2013.10.011_bib41","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/hep.23743","article-title":"Phase 1b study of pegylated interferon \u03bb 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection","volume":"52","author":"Muir","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2013.10.011_bib42","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22835","article-title":"The cyclophilin inhibitor Debio 025 combined with PEG IFN\u03b12a significantly reduces viral load in treatment-naive hepatitis C patients","volume":"49","author":"Flisiak","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2013.10.011_bib43","first-page":"S40","article-title":"Efficacy and safety of the cyclophilin inhibitor DEBIO 025 in combination with pegylated interferon \u03b1 2a and ribavirin in previously null-responder genotype 1 HCV patients","volume":"50","author":"Nelson","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2013.10.011_bib44","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0168-8278(09)60091-X","article-title":"Safety, plasma pharmacokinetics and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection","volume":"50","author":"Hopkins","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2013.10.011_bib45","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/S0168-8278(10)60275-9","article-title":"Short term safety, tolerability, pharmacokinetics and preliminary activity of GS-9450, a selective caspase inhibitor in patients with chronic HCV infection","volume":"52","author":"Manns","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2013.10.011_bib47","doi-asserted-by":"crossref","first-page":"S465","DOI":"10.1016\/S0168-8278(10)61197-X","article-title":"GI-5005 therapeutic vaccine plus PEG-IFN\/Ribavirin significantly improves virologic response and ALT normalization at end of treatment and improves SVR24 compared to PEG-IFN\/Ribavirin in genotype 1 chronic HCV patients","volume":"52","author":"Jacobson","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.mcna.2013.10.011_bib48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.mcna.2013.10.011_bib49","first-page":"404A","article-title":"GI-5005 therapeutic vaccine plus Peg-IFN\/ribavirin improves sustained virological response versus Peg-IFN\/Ribavirin in prior non-responders with genotype 1 chronic HCV infection","volume":"52","author":"Pockros","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2013.10.011_bib50","first-page":"1258A","article-title":"GI-5005 therapeutic vaccine improves deficit in cellular immunity in IL28B Genotype T\/T, treatment naive patients with Chronic hepatitis C genotype 1 when added to standard of care(SOC) PEG-IFN-\u03b1-2a\/Ribavirin","volume":"52","author":"Vierling","year":"2011","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1016\/j.mcna.2014.01.001","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T00:00:00Z","timestamp":1390262400000},"record-id":"41396"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712513001594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712513001594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T14:28:21Z","timestamp":1556720901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712513001594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0025712513001594"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2013.10.011","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}